Plasma Immunity of Mild SARS-CoV-2 Omicron and Delta Pandemic in Thailand

the Safety and Efficacy of Meplazumab in Patients With COVID-19

NCT05113784 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19

NCT05813587 ·Status: COMPLETED ·Phase: PHASE3

Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies

NCT05148806 ·Status: COMPLETED

Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia

NCT04275245 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell)

NCT05616754 ·Status: UNKNOWN ·Phase: PHASE3

Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires

NCT01214876 ·Status: COMPLETED

Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults

NCT02544048 ·Status: COMPLETED

Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

NCT05433285 ·Status: COMPLETED ·Phase: PHASE3

Susceptibility of Gambian Adults to PfSPZ-Challenge Infection in the Controlled Human Malaria Infection Model

NCT03496454 ·Status: COMPLETED ·Phase: NA

Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19

NCT05679492 ·Status: WITHDRAWN ·Phase: PHASE3

ICC-1132 - Candidate Vaccine Against P Falciparum Malaria

NCT00587249 ·Status: COMPLETED ·Phase: PHASE1

Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States

NCT02153996 ·Status: TERMINATED

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

NCT04966871 ·Status: COMPLETED ·Phase: PHASE1

A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313

NCT02532049 ·Status: COMPLETED ·Phase: PHASE1

Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)

NCT01434381 ·Status: COMPLETED ·Phase: PHASE1

Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine

NCT05409261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Malaria Challenge in Healthy Volunteers

NCT01500980 ·Status: COMPLETED ·Phase: PHASE1

Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909

NCT01351948 ·Status: COMPLETED ·Phase: PHASE1

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

NCT03341754 ·Status: COMPLETED ·Phase: PHASE1

Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination

NCT01586169 ·Status: COMPLETED ·Phase: NA

Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines

NCT00443131 ·Status: COMPLETED ·Phase: PHASE2

Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum

NCT00487916 ·Status: COMPLETED ·Phase: PHASE1

AMA1-C1/Alhydrogel + CpG 7909 for Malaria

NCT00344539 ·Status: COMPLETED ·Phase: PHASE1

Effect of Combined Use of Ivermectin and Colchicine in COVID-19 Patients

NCT05246072 ·Status: COMPLETED ·Phase: PHASE4

Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel

NCT04452643 ·Status: WITHDRAWN ·Phase: PHASE3